INSP Quote, Financials, Valuation and Earnings

Electromed has a net margin of 14.69% compared to Inspire Medical Systems's net margin of 12.11%. Inspire Medical Systems's return on equity of 8.4% beat Electromed's return on equity of 15.91%.

Inspire Medical Systems has a consensus price target of $232.93, signalling upside risk potential of 41.22%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 53.46%. Given that Electromed has higher upside potential than Inspire Medical Systems, analysts believe Electromed is more attractive than Inspire Medical Systems.

Inspire Medical Systems has a beta of 1.477, which suggesting that the stock is 47.651% more volatile than S&P 500. In comparison Electromed has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.696%.

Inspire Medical Systems has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inspire Medical Systems pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Inspire Medical Systems quarterly revenues are $239.7M, which are larger than Electromed quarterly revenues of $16.3M. Inspire Medical Systems's net income of $35.2M is higher than Electromed's net income of $2M. Notably, Inspire Medical Systems's price-to-earnings ratio is 95.35x while Electromed's PE ratio is 32.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inspire Medical Systems is 6.22x versus 3.62x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

IRIDEX has a net margin of 14.69% compared to Inspire Medical Systems's net margin of -16.69%. Inspire Medical Systems's return on equity of 8.4% beat IRIDEX's return on equity of -157.91%.

Inspire Medical Systems has a consensus price target of $232.93, signalling upside risk potential of 41.22%. On the other hand IRIDEX has an analysts' consensus of -- which suggests that it could grow by 124.72%. Given that IRIDEX has higher upside potential than Inspire Medical Systems, analysts believe IRIDEX is more attractive than Inspire Medical Systems.

Inspire Medical Systems has a beta of 1.477, which suggesting that the stock is 47.651% more volatile than S&P 500. In comparison IRIDEX has a beta of 0.936, suggesting its less volatile than the S&P 500 by 6.383%.

Inspire Medical Systems has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inspire Medical Systems pays -- of its earnings as a dividend. IRIDEX pays out -- of its earnings as a dividend.

Inspire Medical Systems quarterly revenues are $239.7M, which are larger than IRIDEX quarterly revenues of $11.6M. Inspire Medical Systems's net income of $35.2M is higher than IRIDEX's net income of -$1.9M. Notably, Inspire Medical Systems's price-to-earnings ratio is 95.35x while IRIDEX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inspire Medical Systems is 6.22x versus 0.30x for IRIDEX. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of 14.69% compared to Inspire Medical Systems's net margin of -2.16%. Inspire Medical Systems's return on equity of 8.4% beat Myomo's return on equity of -48.64%.

Inspire Medical Systems has a consensus price target of $232.93, signalling upside risk potential of 41.22%. On the other hand Myomo has an analysts' consensus of $9.25 which suggests that it could grow by 72.58%. Given that Myomo has higher upside potential than Inspire Medical Systems, analysts believe Myomo is more attractive than Inspire Medical Systems.

Inspire Medical Systems has a beta of 1.477, which suggesting that the stock is 47.651% more volatile than S&P 500. In comparison Myomo has a beta of 1.609, suggesting its more volatile than the S&P 500 by 60.902%.

Inspire Medical Systems has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inspire Medical Systems pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

Inspire Medical Systems quarterly revenues are $239.7M, which are larger than Myomo quarterly revenues of $12.1M. Inspire Medical Systems's net income of $35.2M is higher than Myomo's net income of -$260.1K. Notably, Inspire Medical Systems's price-to-earnings ratio is 95.35x while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inspire Medical Systems is 6.22x versus 6.22x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis has a net margin of 14.69% compared to Inspire Medical Systems's net margin of -118.53%. Inspire Medical Systems's return on equity of 8.4% beat Stereotaxis's return on equity of -139.2%.

Inspire Medical Systems has a consensus price target of $232.93, signalling upside risk potential of 41.22%. On the other hand Stereotaxis has an analysts' consensus of $4.50 which suggests that it could grow by 127.27%. Given that Stereotaxis has higher upside potential than Inspire Medical Systems, analysts believe Stereotaxis is more attractive than Inspire Medical Systems.

Inspire Medical Systems has a beta of 1.477, which suggesting that the stock is 47.651% more volatile than S&P 500. In comparison Stereotaxis has a beta of 1.546, suggesting its more volatile than the S&P 500 by 54.601%.

Inspire Medical Systems has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inspire Medical Systems pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

Inspire Medical Systems quarterly revenues are $239.7M, which are larger than Stereotaxis quarterly revenues of $6.3M. Inspire Medical Systems's net income of $35.2M is higher than Stereotaxis's net income of -$7.5M. Notably, Inspire Medical Systems's price-to-earnings ratio is 95.35x while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inspire Medical Systems is 6.22x versus 6.27x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.